Shanxi Bethune Hospital

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Sugammadex on Laparoscopic Bariatric Surgery

Not Applicable

Not yet recruiting

Conditions: Laparoscopic Bariatric Surgery
Sugammadex

Interventions: Drug: Sugammadex
Drug: Neostigmine

First Posted Date: 2024-11-07

Last Posted Date: 2024-11-07

Lead Sponsor: Shanxi Bethune Hospital

Target Recruit Count: 60

Registration Number: NCT06678451

Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study

Not Applicable

Recruiting

Conditions: Aplastic Anemias

First Posted Date: 2024-10-21

Last Posted Date: 2024-10-21

Lead Sponsor: Shanxi Bethune Hospital

Target Recruit Count: 110

Registration Number: NCT06650553

Locations: 🇨🇳
Shanxi Bethune Hospital, Taiyuan, Shanxi, China

Thoracic Paravertebral Block in Daytime Laparoscopic Partial Adrenalectomy

Not Applicable

Recruiting

Conditions: Laparoscopic Adrenalectomy
Day Surgery

Interventions: Procedure: thoracic paravertebral block

First Posted Date: 2024-08-22

Last Posted Date: 2024-10-31

Lead Sponsor: Shanxi Bethune Hospital

Target Recruit Count: 80

Registration Number: NCT06566521

Locations: 🇨🇳
Shanxi Bethune Hospital, Taiyuan, Shanxi, China

Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM

Phase 2

Recruiting

Conditions: Multiple Myeloma in Relapse

Interventions: Drug: Pomalidomide, cyclophosphamide combined with dexametha

First Posted Date: 2024-02-13

Last Posted Date: 2024-02-13

Lead Sponsor: Shanxi Bethune Hospital

Target Recruit Count: 43

Registration Number: NCT06255847

Locations: 🇨🇳
ShanxiBethuneH, Taiyuan, Shanxi, China

JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases

Early Phase 1

Not yet recruiting

Conditions: Autoimmune Diseases

Interventions: Genetic: JY231

First Posted Date: 2024-02-06

Last Posted Date: 2024-02-06

Lead Sponsor: Shanxi Bethune Hospital

Target Recruit Count: 20

Registration Number: NCT06243159

Locations: 🇨🇳
Shanxi Bethune Hospital, Taiyuan, Shanxi, China

Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

Phase 2

Recruiting

Conditions: Hematological Malignancy

Interventions: Drug: CAR-T cell therapy

First Posted Date: 2024-02-02

Last Posted Date: 2024-02-02

Lead Sponsor: Shanxi Bethune Hospital

Target Recruit Count: 30

Registration Number: NCT06238336

Locations: 🇨🇳
ShanxiBethuneH, Taiyuan, Shanxi, China

Clinical Effectiveness of Combining Mindfulness-Based Stress Reduction With Exercise Interventione

Not Applicable

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Behavioral: routine health education
Behavioral: psychological nursing
Behavioral: MBSR therapy
Behavioral: exercise therapy

First Posted Date: 2024-01-25

Last Posted Date: 2024-01-25

Lead Sponsor: Shanxi Bethune Hospital

Target Recruit Count: 60

Registration Number: NCT06224504

Locations: 🇨🇳
Combined Mindfulness-Based Stress Reduction and Exercise Intervention for Improving Psychological Well-being in Chinese Patients with Non-Small Cell Lung Cancer, Taiyuan, Shanxi, China

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Phase 3

Recruiting

Conditions: Relapsed or Refractory Acute Myeloid Leukemia

Interventions: Drug: Selinexor
Drug: Homoharringtonine
Drug: Daunorubicin
Drug: Cytarabine
Drug: Granulocyte Colony-Stimulating Factor
Drug: Aclacinomycin

First Posted Date: 2023-02-13

Last Posted Date: 2024-10-22

Lead Sponsor: Shanxi Bethune Hospital

Target Recruit Count: 50

Registration Number: NCT05726110

Locations: 🇨🇳
Tao Wang, Taiyuan, Shanxi, China

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy